Clinical Trial Details

USOR 17132

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Advanced Cancer
Study Type: Interventional
Phase: III
Study Start Date: 03/29/2018
Study Completion Date: 02/2025

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN).

NCT Number

NCT03452137

Principal Investigator(s)

Mohit Narang, MD

Sponsor(s)

Hoffmann-La Roche

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female